Valuation : Celltrion, Inc.

Market Cap 45,33600Cr 3.31TCr 2.85TCr 2.68TCr 2.44TCr 4.59TCr 3,15000Cr 4.62TCr 32TCr 12TCr 1,59800Cr 12TCr 12TCr 5,29000Cr P/E 2026 *
28.7x
P/E 2027 * 24.9x
Enterprise Value 4.75TCr 3.47Cr 2.99Cr 2.81Cr 2.56Cr 4.81Cr 330.31Cr 4.85Cr 33Cr 13Cr 167.5Cr 13Cr 13Cr 554.6Cr EV / Sales 2026 *
8.67x
EV / Sales 2027 * 7.43x
Free-Float
60.59%
Yield 2026 *
0.4%
Yield 2027 * 0.43%
Manager TitleAgeSince
Chief Executive Officer 65 20/03/2015
Chief Executive Officer 42 26/03/2021
President 50 13/02/2026
Director TitleAgeSince
Chairman 68 -
Director/Board Member 61 01/04/2005
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.32TCr
-1.23%-1.91%+0.98%+17.94% 5.05TCr
-1.81%-3.64%+415.75%+500.16% 4.46TCr
-0.49%+0.10%+41.78%+17.01% 4.31TCr
-2.30%-3.83%+7.74%+72.37% 4.17TCr
-0.94%-1.77%+18.34%+46.84% 3.32TCr
-1.76%-4.66%+24.88%+118.72% 1.68TCr
+6.55%+5.12% - - 1.63TCr
+0.25%-0.98%+11.63%+27.62% 1.46TCr
-2.11%-4.09%+77.59%+38.46% 1.39TCr
Average -0.36%-1.24%+74.84%+104.89% 3.05TCr
Weighted average by Cap. -0.75%-1.05%+88.95%+121.67%

Financials

2026 *2027 *
Net sales 5,48000Cr 400.25Cr 344.61Cr 323.58Cr 295.37Cr 554.89Cr 38TCr 558.86Cr 3.83TCr 1.49TCr 19TCr 1.5TCr 1.47TCr 64TCr 6,29400Cr 459.65Cr 395.76Cr 371.6Cr 339.21Cr 637.24Cr 44TCr 641.81Cr 4.4TCr 1.71TCr 22TCr 1.73TCr 1.69TCr 73TCr
Net income 1,51100Cr 110.34Cr 95Cr 89Cr 81Cr 152.97Cr 10TCr 154.06Cr 1.06TCr 411.26Cr 5.32TCr 414.29Cr 405.28Cr 18TCr 1,76300Cr 128.78Cr 110.88Cr 104.11Cr 95Cr 178.54Cr 12TCr 179.82Cr 1.23TCr 480.01Cr 6.21TCr 483.54Cr 473.03Cr 21TCr
Net Debt 2,19900Cr 160.57Cr 138.25Cr 129.81Cr 118.5Cr 222.61Cr 15TCr 224.2Cr 1.54TCr 598.48Cr 7.75TCr 602.88Cr 589.78Cr 26TCr 1,40900Cr 102.9Cr 89Cr 83Cr 76Cr 142.66Cr 9.79TCr 143.69Cr 985.82Cr 383.56Cr 4.97TCr 386.38Cr 377.98Cr 16TCr
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A